Compare WSO & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSO | PODD |
|---|---|---|
| Founded | 1945 | 2000 |
| Country | United States | United States |
| Employees | 7050 | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 12.7B |
| IPO Year | N/A | 2007 |
| Metric | WSO | PODD |
|---|---|---|
| Price | $427.07 | $174.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 21 |
| Target Price | ★ $399.00 | $341.48 |
| AVG Volume (30 Days) | 489.0K | ★ 990.8K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $3.02 | $24.55 |
| Revenue Next Year | $5.20 | $19.18 |
| P/E Ratio | ★ $34.24 | $49.32 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $323.05 | $158.35 |
| 52 Week High | $494.94 | $354.88 |
| Indicator | WSO | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 30.88 |
| Support Level | $400.37 | N/A |
| Resistance Level | $494.94 | $205.95 |
| Average True Range (ATR) | 16.40 | 7.19 |
| MACD | -0.22 | -1.53 |
| Stochastic Oscillator | 53.82 | 33.80 |
Watsco is the largest HVAC and refrigeration products distributor in North America with approximately 13% market share. The company primarily operates in the United States (90% of revenue) with significant exposure in the Sunbelt states. Watsco also has operations in Canada, Latin America, and the Caribbean. The company's customer base comprises more than 120,000 dealers and contractors serving the replacement and new-construction HVAC/R markets for residential and light-commercial applications. As much as 20% of residential HVAC units are distributed through Watsco in any given year. Revenue is approximately 75%-80% residential HVAC and 20%-25% commercial, with relatively small exposure to more complex "applied" solutions.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.